Definium Therapeutics Financial Statements
NASDAQ: DFTXHealth Care Medicinal Chemicals and Botanical Products USD
36.90+2.72 (+7.96%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 36.90 0.00%
Definium Therapeutics revenue and earnings
Definium Therapeutics reported a net loss of $183.8 million, compared with a loss of $108.7 million a year earlier. Diluted earnings per share came in at -$2.06.
Summary generated from market data by MetaCap's automated system. Methodology
Definium Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Operating Expenses | 166.31M | 103.92M | 93.87M | 66.33M | 93.85M | 33.03M |
| Research & Development | 117.67M | 65.30M | 52.12M | 36.17M | 34.79M | 18.63M |
| Operating Income | -166.31M | -103.92M | -93.87M | -66.33M | -93.85M | -33.03M |
| Interest Expense | 5.48M | 2.28M | 920.00K | — | — | — |
| Other Income (Expense) | -17.48M | -4.76M | -1.87M | 9.54M | -339.00K | -907.00K |
| Pretax Income | -183.79M | -108.68M | -95.73M | -56.80M | -94.19M | -33.94M |
| Income Tax | 0 | — | — | — | -1.16M | — |
| Net Income | -183.79M | -108.68M | -95.73M | -56.80M | -93.04M | -33.94M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| EPS (Basic) | -2.06 | -1.54 | -2.44 | -1.84 | -3.40 | -0.13 |
| EPS (Diluted) | -2.06 | -1.54 | -2.44 | -1.84 | -3.40 | -0.13 |
| Shares Outstanding (Basic) | 89.33M | 70.46M | 39.16M | 30.86M | 27.38M | 266.22M |
| Shares Outstanding (Diluted) | 89.33M | 70.46M | 39.16M | 30.86M | 27.38M | 266.22M |
This table shows 6 annual periods of Definium Therapeutics's income statement, from FY 2025 back to FY 2020, across 12 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow DFTX's reporting calendar. What is a income statement?